[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
May 1964

Effect of Oxymetholone in Refractory Anemia

Author Affiliations


From the Department of Hematology, Hospital de Enfermedades de la Nutrición.

Arch Intern Med. 1964;113(5):721-729. doi:10.1001/archinte.1964.00280110101020

Until recently, the prognosis of refractory anemia could be summarized in the following terms: "Marrow aplasia cannot be reversed by any known means. Supportive therapy with transfusions and antibiotics is usually necessary and, in milder cases, may prolong life until spontaneous recovery of marrow function occurs." 29 With the exception of the rare cases in which splenectomy improved the clinical and hematological picture, the course of the disease was but slightly modified by therapy.17,21,26 The present outlook is brighter since androgenic hormone therapy has been introduced in this condition.31 The testosterone derivatives used (methyltestosterone; testosterone cyclopentylate, enanthate, and propionate; and fluoxymesterone) have several disadvantages consisting of bone-maturating and virilizing actions; some of the derivatives are orally inactive or produce liver damage. In view of this, it seemed advisable to investigate, in patients with medular insufficiency, the therapeutic action of oxymetholone (2-hydroxymethylene-17α-methyldihydrotestosterone), an anabolic hormone with less virilizing activity.